Oyster Point Pharma Reports Q2 2021 Results Including $125M Credit Facility and License Agreement up to $205M
Aug. 05, 2021 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma” or “the Company”) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced its financial results for the second quarter of 2021, and provided…Read More
Read MoreElevation Oncology IPO Raises $115M
June 24, 2021 – Elevation Oncology, Inc. (NASDAQ: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $16.00…Read More
Read MoreVera Therapeutics IPO Raises $47.8M
May 13, 2021 – Vera Therapeutics, Inc. (“Vera”), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00…Read More
Read MoreCompass, Inc. IPO Raises $450M
April 1, 2021 – Compass, Inc. completed its Initial public offering of 25,000,000 of Class A common stock, to begin trading on the NYSE under the symbol COMP. The IPO shares were priced at $18/share. Lead underwriters were Goldman Sachs, Morgan Stanley. and Barclays Capital Inc. The FLG partners Jennifer…Read More
Read MoreJumio Raises $150M in Private Equity
March 23, 2021 – Jumio, the leading provider of AI-powered end-to-end identity verification and eKYC solutions, today announced it secured a $150 million investment from Great Hill Partners, a private equity firm that invests in high-growth, disruptive companies. FLG partner Kenton Chow assisted. Full press release is here.
Read More
Recent News
